Akèy › Maladi Entestinal Anflamatwa
Etid klinik pou Maladi Entestinal Anflamatwa ap rekrite nan Etazini
71 etid pou Maladi Entestinal Anflamatwa ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY18 etid
- Boston, MA15 etid
- Seattle, WA9 etid
- Miami, FL9 etid
- Durham, NC8 etid
- Orlando, FL8 etid
- Houston, TX8 etid
- Atlanta, GA8 etid
- Cincinnati, OH7 etid
- Washington, DC7 etid
- Philadelphia, PA7 etid
- St. Louis, MO7 etid
- Baltimore, MD6 etid
- Pittsburgh, PA5 etid
- San Diego, CA5 etid
- Providence, RI5 etid
- Round Rock, TX5 etid
- Ann Arbor, MI5 etid
- Los Angeles, CA5 etid
- Tyler, TX5 etid
- Mountain View, CA5 etid
- Colorado Springs, CO4 etid
- Lewisville, TX4 etid
- Chicago, IL4 etid
- Garland, TX4 etid
- Cleveland, OH4 etid
- Milwaukee, WI4 etid
- Hartford, CT4 etid
- Fort Worth, TX4 etid
- Tampa, FL4 etid
- Cedar Rapids, IA3 etid
- New Orleans, LA3 etid
- San Antonio, TX3 etid
- Lancaster, CA3 etid
- Tacoma, WA3 etid
- Louisville, KY3 etid
- League City, TX3 etid
- Evanston, IL3 etid
- New Haven, CT3 etid
- Charlotte, NC3 etid
Pa eta
- Arizona6 etid
- Arkansas3 etid
- Colorado5 etid
- Connecticut8 etid
- Florid11 etid
- Georgia9 etid
- Illinois7 etid
- Iowa3 etid
- Kalifòni18 etid
- Kansas3 etid
- Kentucky4 etid
- Lwizyàn6 etid
- Maryland11 etid
- Massachusetts15 etid
- Michigan6 etid
- Minnesota3 etid
- Mississippi3 etid
- Missouri7 etid
- Nevada3 etid
- New Jersey5 etid
- New York21 etid
- North Carolina14 etid
- Ohio15 etid
- Pennsylvania11 etid
- Rhode Island5 etid
- South Carolina4 etid
- Tennessee7 etid
- Texas16 etid
- Utah3 etid
- Virginia6 etid
- Washington10 etid
- Wisconsin4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT06598943Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Ap rekriteEtid obsèvasyon
Laj 18 a 85 · Tout sèks · Mizajou Sep 30, 2026 · NCT07619547A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07845487Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT06619990Immune Regulation in Ulcerative Colitis or Crohn s Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 75 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT00001184Non-nutritive Sweeteners in Inflammatory Bowel Disease
Ap rekriteVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07769437A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT05923073Study of DISC-0974-201 in Participants With IBD and Anemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07368972Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT04685200A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Ap rekriteFaz 3
Laj 2 a 19 · Tout sèks · Mizajou Sep 22, 2026 · NCT04844606A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT06226883Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 21, 2026 · NCT07513181Observational Pharmaco-Epidemiology Research & Analysis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT03813862Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Ap rekriteEtid obsèvasyon
1 Month – 115 Years · Tout sèks · Mizajou Sep 9, 2026 · NCT00001456A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
Ap rekriteFaz 4
3 Weeks · Fanm · Mizajou Sep 8, 2026 · NCT07612267Familial Inflammatory Bowel Disease Early Risk
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 a 55 · Tout sèks · Mizajou Aug 28, 2026 · NCT07791862A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 24, 2026 · NCT05509777Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06274554A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
Ap rekriteEtid obsèvasyon
Laj 18 a 45 · Fanm · Mizajou Aug 11, 2026 · NCT00904878BOOM-IBD2 Pivotal Clinical Trial
Ap rekrite
Laj 18 a 85 · Tout sèks · Mizajou Aug 6, 2026 · NCT06571669HB-adMSCs for the Treatment of Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Aug 6, 2026 · NCT07077746Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07237516Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT02997293Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.